J3379 HCPCS Level II code: Injection, valproate sodium, 5 mg
J3379 is the HCPCS code for “Injection, valproate sodium, 5 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3379Injection, valproate sodium, 5 mg
Short description: Inj, valproate sod, 5 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J3379 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2026
Where J3379 sits
- 1J codesDrugs administered other than orally
- 2Active code J3379Injection, valproate sodium, 5 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3379 mean?
J3379 is the HCPCS code for “Injection, valproate sodium, 5 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3379?
CMS lists J3379’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3379
All J codesJ3371Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mgJ3372Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mgJ3373Injection, vancomycin hydrochloride, 10 mgJ3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mgJ3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mgJ3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mgJ3380Injection, vedolizumab, intravenous, 1 mgJ3385Injection, velaglucerase alfa, 100 unitsJ3386Injection, etuvetidigene autotemcel, per treatmentJ3387Injection, elivaldogene autotemcel, per treatmentJ3389Topical administration, prademagene zamikeracel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatment